Sanofi India Limited (SANOFI)

Loading page…

Sanofi India Limited (SANOFI) · mywealthgrid

About

Sanofi India Limited is a pharmaceutical company in the healthcare sector, operating at meaningful scale with market cap ₹7,458.67 Cr. The company demonstrates strong financial positioning with ROE of 44.07%, zero debt, operating margins ranging 21–32%, and consistent dividend payouts reflecting robust cash generation.

Face value: ₹10

Market cap

₹6,986 Cr

P/E

16.9×

P/B

8.1×

Dividend yield

7.9%

ROE

44.1%

ROCE

48.1%

Debt / equity

OPM

24.4%

EPS (TTM)

₹179.7

Book value

₹374.2

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Share price declined 37.39% over 1 year and trades near 52w low (₹3,097); verify if driven by company-specific issues, sector headwinds, or valuation reset
Operating margin volatility of 10.5 percentage points (21.51–32.08% range) indicates vulnerability to cost, pricing, or product mix shifts
Quarterly revenue range of ₹406–536 Cr represents ~30% variation; assess whether customer/product concentration or demand volatility drive this
Promoter holding of 60.4% against public float of 14.04% may constrain liquidity; verify trading volume adequacy

Generated analysis · source review pending

Growth drivers

OPM improvement from 21.51% (Dec 2025) to 26.34% (Jun 2026) could accelerate net profit if margin level sustains
High ROE of 44.07% and zero debt enable reinvestment of earnings for compounding growth
Quarterly net profits of ₹61.7–102.6 Cr provide capital for organic investments or strategic moves
Verify whether revenue can accelerate beyond recent ₹406–536 Cr range through new product launches or market expansion

Generated analysis · source review pending

2,528 historical price candles were omitted because the exchange source has not been verified.

₹3,031.6-1.3%1Y

Quick read

rule-based

Pros

+Strong return on equity of 51.7% (3-yr avg)
+High return on capital employed of 63.1%
+Healthy operating margin of 24.4%
+Almost debt-free (debt/equity 0)
+Comfortable interest coverage of 313.7×
+Dividend yield of 7.9%
+High promoter holding of 60.4% with no pledge

Cons

−Trading at 8.1× book value

Research score

Structured signal from quality, growth, valuation and momentum.

52/100

Business quality: 93
Growth

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2022	Dec 2023	Dec 2024
	2,770	2,851	2,013
COGS	1,190	1,201	979
Gross profit	1,581	1,650	1,034
	876	846	543
	704	804	491
OPM %	25.4%	28.2%	24.4%
Depreciation	42	40	37
Interest	2	2	2
	204	83	78
Profit before tax	864	846	531
Tax	244	243	118
Tax %	28.2%	28.7%	22.2%
	621	603	413
PAT margin %	22.4%	21.2%	20.5%
EPS (₹)	—	261.8	179.5
EPS adjusted (₹)	—	262.1	179.7
	—	44.7%	93.1%
Annual report	Annual report for Mar 2022	Annual report for Dec 2023	Annual report for Dec 2024

₹ Cr	Dec 2023	Dec 2024
Equity capital	23	23
Reserves	992	838
	0	0
	700	751
Total equity & liabilities	1,715	1,612
	315	313
CWIP	13	18
Investments	0	0
	1,387	1,281
Total assets	1,715	1,612

₹ Cr	Dec 2023	Dec 2024
	230	462
	38	-19
	-878	-553
Net cash flow	-610	-111
Free cash flow	196	425
CFO / Operating profit %	28.7%	94%

Compounded sales growth

7 years: —
5 years: —
3 years: —
1 year: 38%

Compounded profit growth

7 years: —
5 years: —
3 years: —
1 year: 50%

Return on equity

7 years: —
5 years: —
3 years: —
Last year: 48%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2022	Dec 2023	Dec 2024
Margins
Gross margin %	57.1%	57.9%	51.4%
EBITDA margin %	25.4%	28.2%	24.4%
EBIT margin %	23.9%	26.8%	22.6%
PAT margin %	22.4%	21.2%	20.5%
Working capital
Receivable days	—	17	42
Inventory days	—	202	186
Payable days	—	89	151
NWC days	—	130	77
Leverage
Current ratio	—	1.92	1.76
Debt to EBITDA	—	0	0
Debt to equity	—	0	0
Interest coverage	431.8	487.9	313.7
Asset turnover	—	1.66	1.25
Return ratios
Return on assets %	—	35.2%	25.6%
Return on capital employed %	—	78%	48.1%
Return on equity %	—	59.4%	48%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	60.4%	60.4%	60.4%	60.4%	60.4%	60.4%	60.4%	60.4%	60.4%	60.4%	60.4%	60.4%
	6.8%	6.31%	6.11%	5.81%	5.78%	5.63%	5.57%	5.61%	5.57%	5.55%	5.64%	5.69%
	21.69%	21.03%	23.08%	22.79%	22.82%	22.93%	23.02%	23.06%	22.29%	21.31%	21.13%	19.87%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	11.11%	12.26%	10.41%	11%	11%	11.04%	11.01%	10.93%	11.74%	12.74%	12.83%	14.04%
No. of shareholders	—	—	—	—	—	—	—	—	71,395	75,813	75,758	80,005

Promoter holding up 0 percentage points since Sep 2023.

22 deals · 19 Sept 2022 – 24 Sept 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
24 Sept 2026	SANOFI HEALTHCARE INDIA PRIVATE LIMITED	Block	NSE	Buy	35,00,000	₹3,052.00	₹1,068.20 Cr
24 Sept 2026	SANOFI HEALTHCARE INDIA PRIVATE LIMITED	Bulk	NSE	Buy	35,00,000	₹3,052.00	₹1,068.20 Cr
24 Sept 2026	HOECHST GMBH	Bulk	NSE	Sell	35,00,000	₹3,052.00	₹1,068.20 Cr
24 Sept 2026	HOECHST GMBH	Block	NSE	Sell	35,00,000	₹3,052.00	₹1,068.20 Cr
12 Jun 2026	HDFC LIFE INSURANCE COMPANY LIMITED	Bulk	BSE	Sell	2,75,000	₹3,150.00	₹86.63 Cr
12 Jun 2026	NIPPON INDIA MUTUAL FUND	Bulk	BSE	Buy	2,64,118	₹3,150.00	₹83.20 Cr
17 Oct 2022	ISHARES CORE MSCI EMERGING MARKETS ETF	Block	BSE	Buy	38,863	₹5,743.70	₹22.32 Cr
17 Oct 2022	ISHARES CORE EMERGING MARKETS MAURITIUS CO	Block	BSE	Sell	38,863	₹5,743.70	₹22.32 Cr
17 Oct 2022	ISHARES MSCI INDIA SMALL-CAP ETF	Block	BSE	Buy	4,485	₹5,743.70	₹2.58 Cr
17 Oct 2022	ISHARES INDIA SC MAURITIUS COMPANY	Block	BSE	Sell	4,485	₹5,743.70	₹2.58 Cr

1–10 of 22

1 / 3

Mr. Rahul BhatnagarNon-Executive - Independent Director-Chairperson
Mr. Siraj ChaudhryNon-Executive - Independent Director
Ms. Rajani KesariNon-Executive - Independent Director
Mr. Deepak AroraExecutive Director-MD
Mrs. Sudipta ChakrabortyExecutive Director
Mr. Mahadev GawadeExecutive Director
Mr. Eric MansionNon-Executive - Non Independent Director
Mr. Vaibhav KarandikarNon-Executive - Non Independent Director
Mr. Haresh ValaCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

across 4 fund houses

Held by these funds

5.55%

of the company's equity

All mutual funds

9.14%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

8 schemes · 4 fund houses

		Shares
SMALL CAP FUND	Nippon India Mutual Fund	4.8 L	149.92	0.18%	2.086%	-0
PHARMA FUND	Nippon India Mutual Fund	3 L	93.81	0.99%	1.306%	-0
Contra Fund	SBI Mutual Fund	2.52 L	78.59	0.17%	1.094%	-0
Growth Mid Cap FundNEW	Nippon India Mutual Fund	1.81 L	56.53	0.11%	0.787%	—
Innovation Fund	Nippon India Mutual Fund	41,388	12.93	0.42%	0.18%	-7,722
ETHICAL FUND	Tata Mutual Fund	22,295	6.97	0.18%	0.097%	-0
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	246	0.08	0.17%	0.001%	-0
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	27	0.01	0.01%	0%	-0

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

41

Final dividend22 Apr 2026 · ex-date₹48
Interim dividend7 Nov 2025 · ex-date₹75
Final dividend25 Apr 2025 · ex-date₹117
Final dividend3 May 2024 · ex-date₹117
Interim dividend7 Mar 2024 · ex-date₹50
Special dividend28 Apr 2023 · ex-date₹183
Final dividend28 Apr 2023 · ex-date₹194
Special dividend5 Aug 2022 · ex-date₹193
Special dividend12 Apr 2022 · ex-date₹309
Final dividend12 Apr 2022 · ex-date₹181
Final dividend19 Apr 2021 · ex-date₹125
Special dividend19 Apr 2021 · ex-date₹240
Final dividend29 Jun 2020 · ex-date₹106
Special dividend29 Jun 2020 · ex-date₹243
Final dividend25 Apr 2019 · ex-date₹66
Interim dividend6 Aug 2018 · ex-date₹18
Final dividend26 Apr 2018 · ex-date₹53
Interim dividend31 Jul 2017 · ex-date₹18
Final dividend25 Apr 2017 · ex-date₹50
Interim dividend4 Aug 2016 · ex-date₹18
Final dividend13 Apr 2016 · ex-date₹25
Special dividend13 Apr 2016 · ex-date₹22
Interim dividend29 Jul 2015 · ex-date₹18
Special dividend16 Apr 2015 · ex-date₹11
Final dividend16 Apr 2015 · ex-date₹24
Interim dividend31 Jul 2014 · ex-date₹10
Final dividend16 Apr 2014 · ex-date₹35
Interim dividend5 Aug 2013 · ex-date₹10
Final dividend5 Apr 2013 · ex-date₹29
Interim dividend2 Aug 2012 · ex-date₹4
Final dividend10 Apr 2012 · ex-date₹29
Interim dividend3 Aug 2011 · ex-date₹4
Special dividend31 Mar 2011 · ex-date₹28
Final dividend31 Mar 2011 · ex-date₹23
Interim dividend26 Jul 2010 · ex-date₹4
Final dividend7 Apr 2010 · ex-date₹16.5
Interim dividend30 Jul 2009 · ex-date₹3.5
Final dividend6 Apr 2009 · ex-date₹12.5
Interim dividend29 Jul 2008 · ex-date₹3.5
Dividend dividend3 Apr 2008 · ex-date₹12.5
Interim dividend25 Jul 2007 · ex-date₹3.5

1

Board meeting to consider results4 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

19 announcementsExport CSV

11 Aug 2026, 1:24 pmCompany Update

Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

General PDF

Loading announcements…

Ratio	Mar 2022	Dec 2023	Dec 2024
Margins
Gross margin %	57.1%	57.9%	51.4%
EBITDA margin %	25.4%	28.2%	24.4%
EBIT margin %	23.9%	26.8%	22.6%
PAT margin %	22.4%	21.2%	20.5%
Working capital
Receivable days	—	17	42
Inventory days	—	202	186
Payable days	—	89	151
NWC days	—	130	77
Leverage
Current ratio	—	1.92	1.76
Debt to EBITDA	—	0	0
Debt to equity	—	0	0
Interest coverage	431.8	487.9	313.7
Asset turnover	—	1.66	1.25
Return ratios
Return on assets %	—	35.2%	25.6%
Return on capital employed %	—	78%	48.1%
Return on equity %	—	59.4%	48%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Date	Category	Subject	Filing
11 Aug 2026, 1:24 pm	Company Update General	Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015	PDF
10 Aug 2026, 1:04 pm	Company Update Earnings Call Transcript	Announcement under Regulation 30 (LODR)-Earnings Call Transcript	PDF
31 Jul 2026, 2:41 pm	Company Update Change in Management	Announcement under Regulation 30 (LODR)-Change in Management	PDF
23 Jul 2026, 11:30 am	Company Update Analyst / Investor Meet	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation	PDF
23 Jul 2026, 10:45 am	Company Update Resignation of Director	Announcement under Regulation 30 (LODR)-Resignation of Director	PDF
23 Jul 2026, 10:29 am	Company Update Resignation of Chief Financial Officer (CFO)	Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)	PDF
23 Jul 2026, 10:22 am	Company Update Change in Management	Announcement under Regulation 30 (LODR)-Change in Management	PDF
23 Jul 2026, 10:20 am	Company Update Change in Directorate	Announcement under Regulation 30 (LODR)-Change in Directorate	PDF

Sanofi India Limited